STOCK TITAN

Medicus Pharma director Mahaffy acquires 14,534 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Medicus Pharma Ltd. (MDCX) director Patrick J. Mahaffy reported acquiring 14,534 common shares on November 13, 2026, at $1.72 per share under a subscription agreement in a private placement. He reported direct holdings of 15,243 shares after the transaction. No Rule 10b5-1 plan is reported.

Insider MAHAFFY PATRICK J
Role Director
Type Security Shares Price Value
Grant/Award Common Shares, no par value F1 14,534 $1.72 $25K
Holdings After Transaction: Common Shares, no par value — 15,243 shares (Direct)
Footnotes (1)
  1. F1. On November 13, 2026, Patrick J. Mahaffy entered into a subscription agreement with the Issuer, pursuant to which Mr. Mahaffy agreed to purchase 14,534 common shares, no par value, at a purchase price of $1.72 per share in a private placement in which other investors also participated under separate subscription agreements.
Shares acquired 14,534 common shares November 13, 2026
Price per share $1.72 per share Acquisition reported for November 13, 2026
Direct shares following transaction 15,243 shares Reported following the November 13, 2026 transaction
private placement financial
"purchase price of $1.72 per share in a private placement"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
subscription agreement financial
"entered into a subscription agreement with the Issuer"
A subscription agreement is a legal contract in which an investor agrees to buy a specific number of a company’s shares or other securities under set terms, including price, payment method and conditions for closing the sale. It matters to investors because it legally locks in their purchase and the company’s obligations, determines ownership percentage and any investor rights, and can include conditions or promises that affect future control or returns—like signing a detailed purchase order for equity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MDCX shares did director Patrick J. Mahaffy acquire, and at what price?

Patrick J. Mahaffy reported acquiring 14,534 common shares at $1.72 per share on November 13, 2026. His reported direct holdings after the transaction were 15,243 shares.

Was Patrick J. Mahaffy's MDCX share acquisition part of a private placement?

Yes. Mahaffy entered into a subscription agreement for the shares in a private placement, in which other investors also participated under separate subscription agreements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MAHAFFY PATRICK J

(Last)(First)(Middle)
300 CONSHOHOCKEN STATE ROAD
SUITE 200

(Street)
W. CONSHOHOCKEN PENNSYLVANIA 19428

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares, no par value11/13/2026A(1)14,534A$1.7215,243D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. On November 13, 2026, Patrick J. Mahaffy entered into a subscription agreement with the Issuer, pursuant to which Mr. Mahaffy agreed to purchase 14,534 common shares, no par value, at a purchase price of $1.72 per share in a private placement in which other investors also participated under separate subscription agreements.
/s/ Raza Bokhari, as Attorney-in-Fact, for Patrick J. Mahaffy11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading